Mayo study: Strong link found between researchers’ views on diabetes drug and financial conflicts of interest
Almost all — some 94 percent — of the researchers who published favorable medical journal studies and commentaries on the controversial diabetes drug rosiglitazone had financial ties with pharmaceutical companies that manufacture it or similar drugs,